People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. | — | Pharmaceuticals | Growth/Late | $493.0M | $17.9B | 2020 |
| Delfi Diagnostics, Inc. | — | Biotechnology | Series D+ | $365.9M | $235.9M | 2022 |
Elizabeth Homans at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elizabeth Homans on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rishi Gupta | 1 | 12 |
| Greg Yap | 1 | 8 |
| Richard Klausner | 1 | 7 |
| Robert Nelson | 1 | 7 |
| MICHAEL DYBBS | 1 | 5 |
| Justin Kao | 1 | 4 |
| Catherine Friedman | 1 | 3 |
| Hans Bishop | 1 | 3 |
| Stephen Hill | 1 | 3 |
| William Stevens | 1 | 3 |
| Victor Velculescu | 1 | 2 |
| Richard Goold | 1 | 2 |
| Peter Bach | 1 | 2 |
| Margo Roberts | 1 | 2 |
| Jacob Van Naarden | 1 | 1 |
| Nicholas Dracopoli | 1 | 1 |
| Heather Turner | 1 | 1 |
| Nicholas Restifo | 1 | 1 |
| Stan Riddell | 1 | 1 |
| Peter B. Bach | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.